Rusfertide Hepcidin Mimetic: Phase 3 VERIFY Trial Data and FDA Priority Review Status
Rusfertide hit a 77% clinical response rate in the Phase 3 VERIFY trial for polycythemia vera, and FDA Priority Review now targets a Q3 2026 decision.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
Rusfertide is a synthetic hepcidin-mimetic peptide that researchers have been studying as a non-cytoreductive approach to controlling erythrocytosis in polycythemia vera, and it now carries FDA Priority Review status following positive Phase 3 data. Developed by Protagonist Therapeutics in collaboration with Takeda, rusfertide (also referenced in the literature as PTG-300 or TAK-121) targets iron availability rather than bone marrow cell division directly, distinguishing it mechanistically from older cytoreductive agents used in polycythemia vera research.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: Rusfertide is a hepcidin-mimetic peptide that restricts iron availability for red blood cell production; in the Phase 3 VERIFY trial it produced a 77% clinical response rate in polycythemia vera research (versus 33% for placebo), and the FDA has granted Priority Review with a target action date in Q3 2026.
TL;DR:
- Mechanism: mimics hepcidin, binds ferroportin, and restricts iron export to limit erythropoiesis.
- Evidence stage: Phase 2 REVIVE (NEJM, 2024) and Phase 3 VERIFY (n=293) both met primary endpoints.
- Regulatory status: Investigational, FDA Priority Review accepted, PDUFA target in Q3 2026; not 503A-eligible.
- Key finding: VERIFY showed a 77% clinical response rate versus 33% for placebo plus standard of care.
- Designations: Priority Review, Breakthrough Therapy, Orphan Drug, and Fast Track from the FDA.
Mechanism: mimicking the body's iron-regulatory hormone
Hepcidin is the liver-derived hormone that governs systemic iron homeostasis by binding ferroportin, the sole known cellular iron-export channel, and triggering its internalization. Rusfertide is engineered to reproduce this action pharmacologically. By restricting the iron supply available for erythropoiesis, it lowers hematocrit in polycythemia vera without the direct myelosuppressive or cytotoxic effects associated with hydroxyurea or interferon-based cytoreductive therapy. This iron-restriction mechanism is mechanistically distinct from most other injectable peptides in the compound library, which more commonly act through receptor agonism on metabolic or neuroendocrine pathways rather than a transport-protein blockade.
Phase 2 REVIVE and Phase 3 VERIFY: what the trial data shows
The Phase 2 REVIVE trial (PMID 38381675 — "Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera," New England Journal of Medicine, 2024) enrolled phlebotomy-dependent polycythemia vera patients and found that during the randomized-withdrawal phase, 60% of rusfertide-treated participants maintained hematocrit control without phlebotomy, versus 17% on placebo (P=.002); mean maximum hematocrit fell from 50.0% pre-treatment to 44.5% on active drug.
The Phase 3 VERIFY trial (NCT05210790, n=293) followed up on that signal at larger scale, reporting that rusfertide plus standard of care produced a 77% clinical response rate — defined as freedom from phlebotomy eligibility during weeks 20–32 — compared with 33% for placebo plus standard of care. VERIFY met its primary endpoint and all four key secondary endpoints. A roughly four-year REVIVE/THRIVE long-term extension dataset was submitted alongside the pivotal data package as part of Takeda's New Drug Application.
For researchers tracking how this evidence stacks up against other investigational peptides moving through active trials, the site's trial tracker tool indexes registry-level status across the compounds covered here, including ongoing Phase 2 work on peptides like MOTS-c, which is being studied for a different metabolic indication using a distinct AMPK-linked mechanism.
Regulatory status and what Priority Review means
Rusfertide remains investigational. The FDA accepted Takeda's New Drug Application and granted Priority Review status, with a PDUFA target action date in Q3 2026 (approximately August 2026), alongside Breakthrough Therapy, Orphan Drug, and Fast Track designations. Priority Review shortens the FDA's standard review clock but does not guarantee approval; it signals that the agency considers the submitted data package for a serious condition significant enough to warrant expedited evaluation. If approved, rusfertide would enter the market as a branded specialty injectable rather than a 503A-eligible compounding substance, placing it in a different regulatory category from peptides like tesamorelin, which already carries full FDA approval and has been evaluated in the broader pharmacologic literature on body-composition interventions (PMID 41598480). Researchers interested in the general FDA pathway that separates approved drugs, 503A compounding candidates, and orphan-indication biologics can find additional background in the site's 503A bulk drug substance explainer.
Frequently asked questions
Q: What condition is rusfertide being studied for?
A: Rusfertide is being investigated for polycythemia vera, a chronic myeloproliferative neoplasm marked by excess red blood cell production (erythrocytosis). Its research use is centered on controlling hematocrit without relying on repeated therapeutic phlebotomy or cytoreductive drugs.
Q: How does rusfertide's mechanism differ from hydroxyurea?
A: Hydroxyurea works as a cytoreductive agent that suppresses bone marrow cell proliferation broadly. Rusfertide instead mimics hepcidin to block iron export via ferroportin, restricting the iron supply available for red blood cell production without direct myelosuppressive action.
Q: What were the results of the Phase 3 VERIFY trial?
A: VERIFY (NCT05210790, n=293) found a 77% clinical response rate — defined as freedom from phlebotomy eligibility during weeks 20–32 — for rusfertide plus standard of care, versus 33% for placebo plus standard of care, meeting its primary endpoint and all four key secondary endpoints.
Q: Is rusfertide FDA approved?
A: Not yet. Rusfertide is investigational. The FDA has accepted Takeda's New Drug Application and granted Priority Review, with a target PDUFA action date in Q3 2026, but final approval has not been granted as of this writing.
Q: Is rusfertide eligible for 503A compounding?
A: No. Rusfertide's regulatory profile is tracked as "Not 503A Eligible" in the compound library, since it is being developed as a branded specialty injectable through the standard FDA New Drug Application pathway rather than as a bulk drug substance for compounding pharmacies.
See also:
- What Is the FDA 503A Bulk Drug Substance List? A Researcher's Guide — background on how compounds like rusfertide differ from 503A-eligible compounding substances.
- NCT07505745 Phase 2a Trial: MOTS-c Insulin Sensitivity Research Data — another registry-level look at an investigational peptide moving through active clinical trials.
- BPC-157 ClinicalTrials.gov Registry: NCT07437547 Status & Full Trial History — a comparable registry-based trial history for a different research peptide.
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.